Interleukin-1 receptors and receptor antagonist in haemodialysis

Nephrology Dialysis Transplantation

Volumn 12, Issue 1, 1997, Pages 111-118

  Donati, D ^a,c,e,f   Degiannis, D ^b,c   Mazzola, E ^a,e   Gastaldi, L ^a   Raskova, J ^c   Raska Jr , K ^c,d   Camussi, G ^e  

^a OSPEDALE DI CIRCOLO   (Italy)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

^f Azienda Sanitaria Locale di Varese   (Italy)

Author keywords

Haemodialysis; Interleukin 1 receptor; Interleukin 1 receptor antagonist; Interleukin 1

Indexed keywords

CUPROPHANE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; POLYSULFONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIALYSIS MEMBRANE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LYMPHOCYTE; MALE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELLULOSE; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; KIDNEY, ARTIFICIAL; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; MONOCYTES; POLYMERS; RECEPTORS, INTERLEUKIN-1; RENAL DIALYSIS; SIALOGLYCOPROTEINS; SULFONES; UREMIA;

EID: 0031031709     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.1.111     Document Type: Article

References (49)

1. Henderson LW, Koch KM, Dinarello CA, Shaldon S. Hemodialysis hypotension: the interleukin hypothesis. Blood Purif 1983; 1: 3-8
2. Dinarello CA, Koch KM, Shaldon S. Interleukin-1 and its relevance in patients treated with hemodialysis. Kidney Int 1988; 33(24): S21-S26
3. Dinarello CA. Cytokines: Agents provocateurs in hemodialysis. Kidney Int 1992; 41: 683-694
4. Hakim RM, Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484-494
5. Lonnemann G, Bingel M, Koch KM, Shaldon S, Dinarello CA. Plasma interleukin-1 activity in humans undergoing hemodialysis with regenerated cellulosic membranes. Lymphokine Res 1987; 6: 63-70
6. Bingel M, Lonnemann G, Koch KM, Dinarello CA, Shaldon S. Plasma interleukin activity during hemodialysis: the influence of dialysis membrane. Nephron 1988; 50(4): 273-276
7. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor Kidney Int 1990; 37: 116-125
8. Donati D, Degiannis D, Homer L, Raska K Jr, Raskova J. Production and kinetics of interleukin-1 in hemodialysis. Am J Nephrol 1991; 11: 451-458
9. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1β, TNFα and their specific inhibitors in undialysed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896
10. Luger A, Kovarik J, Stummvoll, Urbanska A, Luger TA. Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987; 32: 84 88
11. Haeffner-Cavaillon N, Cavaillon JM, Ciancioni C, Bade F, Delons S, Kazatchkine MD. In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989; 35: 1212-1218
12. Tetta C, Camussi G, Turello E et al. Production of cytokines in hemodialysis. Blood Purif 1990; 8: 337-346
13. Blumenstein M, Ziegler-Heitbrock et al. Different activation of monocytes in haemodialysis patients exposed to different types of membranes. Scand J Immunol 1990; 31: 183-190
14. Donati D, Degiannis D, Combates N, Raskova J, Raska K Jr. Evidence of mononuclear cell activation by hemodialysis. ASAIO Trans 1991; 37: M386-M387
15. Donati D, Degiannis D, Combates N, Raskova J, Raska K Jr. Effects of hemodialysis on activation of lymphocytes: analysis by an in vitro dialysis model. J Am Soc Nephrol 1992; 2: 1490-1497
16. Nockher WA, Scherberich JE: Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Kidney Int 1995; 48: 1469-1476
17. Bingel M, Lonnemann G, Shaldon S, Koch KM, Dinarello CA. Human interleukin-1 production during hemodialysis. Nephron 1986; 43: 161-163
18. Lonnemann G, Bingel M, Floege J, Koch KM, Shaldon S, Dinarello CA. Detection of endotoxin-like interleukin-1-inducing activity during in vitro dialysis. Kidney Int 1988; 33: 29-35
19. Veech RL, Gitomer WL. The medical and metabolic consequences of administration of sodium acetate. Adv. Enzyme Regul 1988; 27: 313-343.
20. Okusawa S, Dinarello CA, Yancey KB et al. C5a induction of human IL-1: synergistic effect with LPS or interferon-γ. J Immunol 1987; 139: 2635-2642
21. Lonnemann G, Koch KM, Shaldon S, Dinarello CA. Studies of the ability of hemodialysis membranes to induce, bind and clear human interleukin-1. J Lab Clin Med 1988; 112: 76-86
22. Powell AC, Bland L, Oettiger CW et al. Lack of elevation of interleukin 1-β or tumor necrosis factor-α during unfavorable hemodialysis conditions. J Am Soc Nephrol 1991; 2: 1007-1013
23. Holmes C, Evans R, Ross D, Frankamp P: Plasma IL-1 and TNF levels during high flux hemodialysis with cellulose triacetate membranes. Kidney Int 1990; 37: 301
24. Blumenstein M, Schmidt B, Ward RA, Ziegler-Heitbrock HW, Gurland HJ. Altered interleukin-1 production in patients under-going hemodialysis. Nephron 1988; 50(4): 277-281
25. Pearson FC, Dubczac J, Weary M, Anderson J. Determination of endotoxin levels and their impact on interleukin-1 generation in continous ambulatory peritoneal dialysis and hemodialysis. Blood Purif 1988; 6(3): 207-212
26. Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA. Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990; 37: 85-93
27. Ward RA, Schmidt B, Blumenstein M, Gurland HJ. Evaluation of phagocytic cell function in an ex vivo model of hemodialysis. Kidney Int 1990; 37: 776-782
28. Dower SK, Urdal DL. The Interleukin-1 receptor. Immunol Today 1987; 8: 46-50
29. Shirakawa F, Tanaka Y, Ota T, Suzuki H, Eto S, Yamashita U. Expression of interleukin-1 receptors on human peripheral T cells. J Immunol 1987; 138: 4243-4248
30. Tanaka Y, Shirakawa F, Oda S, Yamashita U. Expression of IL-1 receptors on human peripheral B cells. J Immunol 1989; 142: 167-172
31. Uhl J, Newton RC, Gin JG, Sandlin G, Horuk R. Identification of IL-1 receptors on human monocytes. J Immunol 1989; 142: 1576-1581
32. Dinarello CA, Ikejima T, Warner SJC et al. Interleukin-1 induces interleukin-1. Induction of circulating interleukin-1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987; 139: 1902-1907
33. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652
34. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106-113
35. Seckinger P, Lowenthal JW, Williamson K, Dayer JM. McDonald HR. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 1987; 139: 1546-1549
36. Eisenberg SP, Evans RJ, Arend WP et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341-346
37. Pereira BJG, Poutsiaka DD, Strom JA et al. In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int 1992 242: 1419-1424
38. Donati D, Degiannis D, Homer L, Gastaldi L, Raskova J, Raska K Jr. Immune deficiency in uremia: interleukin-2 production and responsiveness and interleukin-2 receptor expression and release. Nephron 1991; 58: 268-275
39. Donati D, Degiannis D, Raskova J, Raska K Jr. Uremic serum effects on peripheral blood mononuclear cell and purified T lymphocytes responses. Kidney Int 1992; 42: 681-689
40. Pereira BJG. Implications of cytokine measurements during in vitro and clinical haemodialysis. Nephrol Dial Transplant 1995; 10: 18-26
41. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954-960
42. Kalechman Y, Gofter U, Srendi B, Levi J: Enhanced cytokine production by erythropietin. J Am Soc Nephrol 1990; 1: 387
43. Poutsiaka DD, Clark DD, Vannier E, Dinarello CA. Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991; 78: 1275-1281
44. Lonnemann G, Floege J, Schindler R et al. : Passage of cytokine-inducing E. coli fragments through various hemodialysis membranes. Am Soc Nephrol 21st Annual Meeting San Antonio 1988, abstr no. 143
45. Lazarus JM, Owen WF. Role of bioincompatibility in dialysis morbidity and mortality. Am J Kidney Dis 1994; 24: 1019-1032
46. Pascual M, Tolkoff-Rubin N, Schifferli JA. Is adsorbtion an important characteristic of dialysis membranes? Kidney Int 1996; 49: 309-313
47. Lonnemann G, Schindler R, Lufft V, Mahiout A, Shaldon S, Koch KM. The role of plasma coating on the permeation of cytokine-inducing substances through dialyser membranes. Nephrol Dial Transplant 1995; 10: 207-211
48. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 1990; 85: 1694-1697
49. McIntyre KW, Stepan GJ, Kolinsky DK et al. Interleukin-1 receptor antagonist blocks acute inflammatory responses to IL-1 and other agents in vivo. J Exp Med 1991; 173: 931-939